Information Provided By: 
Fly News Breaks for September 1, 2017
VNDA
Sep 1, 2017 | 08:39 EDT
JMP Securities analyst Jason Butler says that the risk/reward ratio of Vanda stock is attractive ahead of the expected results of a Phase 2 trial evaluating tradipitant to treat pruritus in atopic dermatitis. The analyst says that the risk/reward ratio is positive due to the stock's attractive valuation and the chances of the drug's success. He raised his price target on the shares to $24 from $22 and keeps an Outperform rating on the stock.
News For VNDA From the Last 2 Days
